Budget
€100 — €0
EP Access
0
accredited persons
Staff
1
0.25 FTE
EU Grants
None
Mission & Goals
We are a commercial-stage, global, fully-integrated biopharma company developing a deep pipeline of differentiated therapies for the treatment of severe autoimmune diseases. By combining our suite of antibody engineering technologies with the disease biology expertise of our research collaborators, we aim to translate immunology breakthroughs into a pipeline of novel antibody-based medicines through our discovery engine, the IIP. We have a particular focus on rare, autoimmune diseases that fit into our growing commercial franchises focused on neurology, hematology and rheumatology, dermatology and nephrology.
EU Legislative Interests
Implementation of the Reform of the General Pharmaceutical Legislation and HTA Regulation/EU JCA. Following the EU Biotech Act.
Communication Activities
argenx is supportive of disease awareness activities in the area of autoimmunity, both through our own activities and through supporting patient groups.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
EUCOPE https://www.eucope.org/ EURORDIS (ERTC) https://www.eurordis.org/ European Business Summits https://ebsummits.eu/
Organisation Members
n.a.
Additional Information
FTI supports argenx with legislative monitoring and argenx participation in external events.
Commissioner Meetings
No recorded meetings with EU commissioners.